Objective: To examine the effects of non-steroidal anti-inflammatory drugs (NSAIDS) on nitric oxide (NO) and prostaglandin E2 (PGE2) production in chondrocytes from three different species.
Introduction
Inducible nitric oxide synthase (iNOS) plays an important role in inflammation, host-defense responses, and tissue repair [1] . Nitric oxide (NO) formation is increased during inflammation (e.g., rheumatoid arthritis, ulcerative colitis or Crohn's disease) and several classic inflammatory symptoms such as erythema and vascular leakiness [2] .
The role of NO has been well demonstrated in various animal models of arthritis [3, 4] . The increased production of NO characteristic of the rodent models of arthritis has been observed in human studies. Mean serum nitrite concentrations in individuals affected by rheumatoid arthritis (RA) and osteoarthritis (OA) are significantly higher than those observed in normal controls [5] . In both disease groups, nitrite concentrations were significantly higher in synovial fluid than serum, implying synthesis of NO within diarthrodial joint(s) where both synoviocytes and chondrocytes have been implicated as sites of increased NO production [6, 7] . Previous studies have also shown that OA/RA-affected cartilage in ex vivo conditions release NO in sufficient quantities to cause cartilage dysfunction [6, 7] . Recent studies have suggested that superficial and deep human and bovine articular chondrocytes show differential production of NO [8, 9] . Excessive concentrations of nitric oxide exert profound effects on chondrocyte functions, including: down regulation of collagen synthesis [10] , inhibition of actin polymerization [11] , down regulation of interleukin IL-1RA expression [12] and induction of apoptosis [13] . Furthermore, two groups have independently presented evidence to suggest that NO induces the synthesis of matrix metalloproteases by monolayer cultures of articular chondrocytes [14, 15] . These manifestations induced by NO, collectively may be a possible mechanism of pathological neovasculization in arthritis.
Although non-steroidal anti-inflammatory drugs (NSAIDS) clearly inhibit the synthesis and release of prostaglandins, these actions are not sufficient to explain all the anti-inflammatory effects of NSAIDS. For example, NSAIDS also inhibit activation of neutrophils, which release inflammatory mediators other than prostaglandins [16] .
We have recently observed that several antiinflammatory drugs, (namely salicylates, glucocorticoids and tetracyclines) inhibit iNOS expression in murine macrophages stimulated with lipopolysaccharides (LPS) [17] . In the present study, we investigated the capacity of NSAIDS to inhibit spontaneous release of NO and prostaglandin E 2 (PGE 2 ) by OA-affected cartilage and rat chondrosarcoma cells (in ex vivo conditions). We also investigated the action of NSAIDS on in vitro cytokine [IL-1b and tumor necrosis factor (TNFa)] + endotoxin stimulated bovine chondrocytes producing NO and PGE 2 . We report that aspirin, sodium salicylate and tenidap, but not indomethacin, inhibit NO production in human OA-affected cartilage, chondrosarcomas, and bovine chondrocytes. The failure of glucocorticoid to inhibit NO production in human chondrocytes, rat chondrosarcomas and bovine chondrocytes is distinct from the previous report of its effects on murine macrophages.
Methods

reagents and cell lines
RPMI-1640 and Ham's F-12 were purchased from Mediatech Inc. (Hernden, VA, U.S.A.). The endotoxin level in this media was Q 0.01 ng/ml. LPS, NSAIDS and steroids were obtained from Sigma (St. Louis, MO, U.S.A.) Cytokines were purchased from Fischer Scientific (Pittsburgh, PA, U.S.A.). Tenidap was kindly provided by Pfizer, Inc. (Groton, CT, U.S.A.).
procurement of human cartilage
Cartilage slices were taken from the knees (tibial plateau and femoral condyle) of patients with the diagnosis of advanced OA (age 50-70 years) who were undergoing knee replacement surgery.
procurement of bovine chondrocytes
The bovine cartilage was obtained from young calfs. Isolation of bovine chondrocytes from hoofs was carried out by standard methods [18, 19] with minor modifications. Briefly, normal bovine cartilage was washed in RPMI-1640 and cut into small pieces and digested with enzymes. Cartilage pieces were incubated with trypsin (0.25%) in RPMI-1640 (Gibco BRL, Gaithersburg, MD, U.S.A.) for 30 min at 37°C before they were washed and re-incubated in hyaluronidase (0.2%) and collagenase (0.2%), dissolved in RPMI-1640 containing 5% fetal bovine serum (FBS) for 16 h at 37°C with continuous agitation (100 rpm). The cells were passed through 75 mm nylon mesh and washed twice with PBS to remove cell debris. The released cells were suspended in RPMI 1640 + 10% FBS + antibiotics and plated in a 24-well plate (Becton Dickinson, Lincoln Park, NJ, U.S.A.) at a density of 5 × 10 5 cells/2.0 cm 2 . After 48 h, the medium was changed and the cells were preincubated in fresh media with various modulators (NSAIDS) for 2 h before stimulating them with IL-1b (1 ng/ml) + TNFa (100 U/ml) and LPS 100 mg/ml) and analyzed for NO and PGE2 levels at 48-72 h of post stimulation. Ethanol was used as a carrier for the NSAIDS and carrier concentration was maintained ( Q 0.01% v/v) in the cultures. Equivalent amount of ethanol was also added to the control cultures. Culture media were assayed for NO and PGE 2 at different time intervals.
isolation and maintenance of rat chondrosarcoma cells
A Swarm rat chondrosarcoma cell line was maintained in Sprague-Dawley rats as previously described [20] . Briefly, 100 g Sprague-Dawley male rats were subcutaneously implanted with the Swarm rat chondrosarcoma. The Swarm rat chondrosarcoma is a well-differentiated malignant tumor that resembles a well-differentiated human chondrosarcoma [21] . After 3 weeks, the animals were sacrificed by CO 2 asphyxiation and tumor harvested using sterile technique. The solid tumor was minced with scissors, centrifuged, and digested with 0.5 mg/ml hyaluronidase (Sigma, MO, U.S.A.) for 10 min followed by 0.2% (w/v) collagenase (Worthington Biochem. Co., NJ, U.S.A.) for 2 h in Hams-F12 media (Life Technologies Inc., Grand Island, NY, U.S.A.), 10 mm Hepes, pH 7.4, containing 50 mg/ml gentamicin in a Spinner culture flask at 37°C. The cells were filtered (150 mm nylon mesh) to remove remaining large cellular debris.
Cells were washed and resuspended in Hams-F12 media, 50 mg/ml gentamicin, 10 mm Hepes, pH 7.4, containing 1% fetal calf serum (FCS) at a final concentration of 5 × 10 5 /ml. The cells were then transferred to a 24-well cell culture plates (5 × 10 5 cells/well) and allowed to attach for 24 h. After 24 h, the medium was changed and NSAIDS were added. Ethanol was used as a carrier.
human oa-explant assay Total knee articular cartilage from tibial plateau and femoral condyle were harvested from OA-affected patients. The cartilage was mixed and cut into 3-mm discs and four to six discs were placed in triplicate or quadruplicate, in a 24-well plate in 2.0 ml Ham's F-12 medium supplemented with 0.2% endotoxin free human albumin, 10 mm Hepes at pH 7.4 and antibiotics in the presence of various modulators, as previously described [6, 22] . The NSAIDS, tenidap, and glucocorticoids were used at pharmacologically relevant concentrations in ethanol [ Q 0.01% (v/v) final concentration] as carrier. Equivalent amount of ethanol was added in all cultures. determination of pge 2 and nitrite PGE 2 was determined in the culture supernatant using a radio-immunoassay (RIA) kit (Sigma, MO, U.S.A.) according to the manufacturer's instructions. The detection limit was 1.0 pg/ml. NO production was measured by estimating the stable NO metabolite, nitrite, in conditioned medium, by a modified Griess reaction [23] . The values were expressed as micromolar nitrite or ng/ml PGE 2 released per 100 mg wet weight of cartilage and 5 × 10 5 of chondrocytes.
statistical analysis
The data represents a minimum of one of the two experiments performed from separate OA-affected cartilage samples. All experiments using cartilage slices, rat chondrosarcoma cells or bovine chondrocytes were performed in triplicate or quadruplicate for each parameter studied. Data are expressed as mean 2 s.d. and statistical analysis was performed using GraphPAD Software (v 1.14). The t test or non parametric (Mann-Whitney or Wilcoxon) test were performed for all the experiments.
Results
We have recently reported that aspirin and sodium salicylate, but not indomethacin could inhibit NO production in murine macrophages in a PGE 2 /COX-2 independent fashion [17] . We have now extended those studies to three chondrocyte systems, each of different species. These include human OA-affected cartilage, Swarm rat chondrosarcoma cells and bovine chondrocytes.
In an effort to elucidate the effect of NSAIDS on NOS expression and function in cartilage and chondrocytes, we have selected four known NSAIDs: an acetylated salicylate (aspirin, an effective inhibitor of COX-2 at the concentrations studied); a non-acetylated salicylate (sodium salicylate, a less effective inhibitor of COX-2) indomethacin (a potent inhibitor of COX-2) and tenidap (an anti-inflammatory drug that inhibits COX-2 as well as IL-1b production) [24] . We tested the hypothesis that NSAIDS, which inhibited NO production in murine macrophages also modulates NOS in cartilage and chondrocytes in a COX-2 independent manner across species. Salicylates, indomethacin and tenidap, which reach therapeutic concentrations in plasma of 1-3 mm, 5-20 mm, and 30 mm, respectively [25] were tested for their capacity to inhibit NO production at the clinically relevant concentrations.
For the present study we selected three model systems for the study of chondrocytes: (a) human OA-affected cartilage, (b) rat chondrosarcoma cells and (c) bovine chondrocytes. In the OA-affected cartilage and rat chondrosarcoma cells, the NO (induced in vivo) was spontaneously released in ex vivo conditions [6, 26] . The NOS isoforms expressed in OA-affected cartilage and rat chondrosarcoma cells are different in view of the 150 kDa OA-NOS in OA-affected cartilage [6] and 133 kDa iNOS in the rat chondrosarcoma cells [26] . The third model system was bovine chondrocytes, which when grown in monolayer culture, produces NO (and express a 133 kDa iNOS) upon in vitro stimulation with cytokines + endotoxin (Fig. 1) .
effect of nsaids on no production in oa-affected cartilage under ex vivo conditions
Human OA-affected cartilage explants in ex vivo conditions were supplemented with aspirin, sodium salicylate and indomethacin as shown in Tables I and II . The spontaneous release of NO was monitored at different time intervals. As expected, time dependent spontaneous release of NO in Fig. 1 . Western blot analysis of iNOS from murine macrophages and bovine chondrocytes. Murine macrophages (RAW 264.7 cells) were stimulated with 1 mg/ml of LPS for 24 h and cells were harvested. Bovine chondrocytes were seeded for 48 h. After 48 h the adherent cells were stimulated with IL-1b (1 ng/ml) + TNFa (100 U/ml) and LPS (100 mg/ml) for 48 h before the cells were harvested. The cell free extracts were prepared as previously described [25] . One hundred micrograms of protein was loaded on the sodium dodecyl sulfate-polyacrylamide gel (SDS-PAGE) and western blotted using an anti-iNOS monoclonal antibody from Transduction Labs (Lexington, KY, U.S.A.) which cross reacts with bovine 133 kDa iNOS.
consistently and significantly inhibited the spontaneous release of NO in OA-affected cartilage, but showed variable effects (0-30% inhibition at similar concentrations) in murine macrophages [27] . OA-affected cartilage spontaneously releases significant quantities of PGE 2 via upregulation of COX-2 not seen in normal cartilage [22] . We therefore tested the ability of these NSAIDS to inhibit spontaneously released PGE 2 in OA-affected cartilage in ex vivo assays. As expected, aspirin (1-3 mm), sodium salicylate (1-3 mm) and indomethacin (20 mm) significantly inhibited PGE 2 production (by q 90%) ( Table III) .
The effect of dexamethasone was examined on NO production in OA-affected cartilage explants. One micromolar of dexamethasone, which significantly inhibited PGE 2 production, had no significant effect on the spontaneous release of NO in the same explant (Table III) .
Tenidap has recently been reported to inhibit synthesis of various cytokines which include IL-1b and IL-6 [24] . In three separate experiments tenidap (at 30 mm) also significantly inhibited the spontaneous release of NO from OA-affected cartilage. Tenidap also significantly inhibited the IL-1b mediated NO production in OA-affected cartilage (Table IV) .
effect of nsaids on inos expressed in rat chondrosarcoma in ex vivo conditions
The rat chondrosarcoma when maintained in rats (in vivo) shows upregulation of iNOS expression and spontaneously releases NO in ex vivo conditions in the absence of any stimulus OA-affected cartilage could be inhibited with pharmacological relevant concentrations of aspirin, sodium salicylate, but not indomethacin. The NOS competitive inhibitor (L-NMA) blocked NO release in both experiments. These results (with respect to the effects of aspirin and indomethacin) were similar to those previously seen with murine macrophages stimulated with LPS in the presence of NSAIDS [27] . Sodium salicylate (at 2-3 mm) [26] (Table V) . L-NMA significantly inhibits the spontaneous release of NO in ex vivo conditions. Rat chondrosarcoma cells were exposed to various NSAIDS in ex vivo conditions to examine their effects on NO production. Aspirin and sodium salicylate, but not indomethacin, significantly inhibited (in a time-and dose-dependent manner) the release of NO from the rat chondrosarcoma cells cultured in ex vivo conditions. In contrast, hydrocortisone (at 1 mm) did not inhibit the NO production in chondrosarcoma cells.
effect of nsaids on bovine chondrocytes stimulated with cytokine + endotoxins in in vitro conditions
We examined the expression of iNOS in bovine chondrocytes stimulated with cytokine + endotoxin. Bovine chondrocytes and murine macrophages expressed a 133 kDa iNOS as shown in Fig. 1 . Bovine chondrocytes grown in monolayer for 48 h were stimulated with IL-1b + TNFa + LPS in the presence and absence of NSAIDS, and the levels of NO and PGE 2 accumulated in the medium were examined at different time intervals. Aspirin, sodium salicylate, and tenidap, but not indomethacin or hydrocortisone, significantly inhibited the accumulation of NO in the medium (Table  VI) . The concentration of indomethacin and hydrocortisone was sufficient to inhibit PGE 2 production in these cells at 72 h.
Discussion
Our experiments indicate that selected antiinflammatory drugs, including the salicylates and tenidap, inhibit NO production by chondrocytes of three species: human, rats and bovine (Table VII) . This effect is not due to the shared capacity of these drugs to inhibit COX-2 dependent prostaglandin production in these cells, since neither indomethacin nor glucocorticoids (at concentrations sufficient to inhibit PGE 2 production) inhibited NO release. This particular observation is in contrast with the capacity of glucocorticoid to inhibit iNOS expression in variety of other cell types (e.g., macrophages, hepatocytes, and mesangial cells) across species [28] [29] [30] [31] . These results suggest that the beneficial effects of glucocorticoids seen in arthritis may not involve the modulation of NO in cartilage and chondrocytes.
The current data is consistent with previous results which indicate that NSAIDS, particularly the salicylates, exert diverse 'prostaglandin-independent' effects which may contribute to their anti-inflammatory properties [16, 32] . Recently, effects of currently available anti-inflammatory drugs on nitric oxide production have emerged as an additional property of these agents. For example, we have reported [27] that salicylates, but not indomethacin, inhibit NO production in LPS-stimulated murine macrophages. In those studies, aspirin consistently inhibited the expression of iNOS protein, whereas the effects of sodium salicylate on iNOS expression was more variable. In addition, aspirin, but not sodium salicylate, inhibited the specific activity of iNOS in cell free extracts, most probably due to the direct acetylation of iNOS by aspirin [27] . These data are consistent with those of Aeberhard, et al. [33] , and Kepka-Lenhart, et al. [34] who have reported that both aspirin and sodium salicylate (20 mm) inhibited NO production and expression of iNOS protein in murine macrophages. As was the case in our prior studies [27] , these investigators observed that salicylates decreased iNOS protein without inhibiting the amount of iNOS mRNA. The observation that salicylates inhibit NO production at a translational step, but not at a transcriptional step, was confirmed in hepatocytes [35] . Finally, other investigators have also demonstrated that the capacity to inhibit NOS is not a property common to all NSAIDS. In rat cardiac fibroblasts, for example, aspirin and sodium salicylate, but not indomethacin or acetaminophen, inhibited cytokine-induced nitrite accumulation in a time and dose-dependent manner (IC 50 0 1 mm) [36] . Thus, the consistent finding in the literature is that salicylates, but typically not indomethacin, inhibit NO production in a variety of cell types, including chondrocytes, macrophages, hepatocytes and fibroblasts, most likely via effects on translation. Our observation that tenidap is also an effective inhibitor of NO production, indicates that this is not a property of salicylates alone, and may be shared by other classes of anti-inflammatory agents. Our results have shown that intra-articular IL-1b produced by OA-affected chondrocytes upregulates endogenous NO production which can be blocked by type I soluble IL-1bR (but not soluble TNFaR). Spontaneous production of NO by OA cartilage can also be blocked by cytokine suppressive anti-inflammatory drugs: CSAID which inhibit p38 kinase [37] .
Our current experiments also demonstrate that Tenidap, which is known to inhibit PGE 2 production [38] , and synthesis of IL-1b and IL-6 [24] also inhibits another pleiotropic inflammatory molecule: NO. The possibility that the inhibition of NO production by tenidap is due to the inhibition of the expression of IL-1b cannot be ruled out by our experiments. It should be noted that aspirin which inhibits the spontaneous release of NO in OA-affected cartilage, like tenidap, also blocked the IL-1b induced NO production in OA-affected cartilage. This is not surprising because previous studies have shown that aspirin in murine macrophages block NOS expression at the translational level and probably also directly at the enzyme level by acetylating the enzyme to render it inactive [27] .
What are the implications of these observations that salicylates and tenidap, but not indomethacin, inhibit NO production by chondrocytes, particularly that produced by OA cartilage? Differences among currently available anti-inflammatory agents with regard to NOS inhibition may be important since several studies have shown that inhibition of excess NO production in cartilage may have a 'chondroprotective role' [10] [11] [12] [13] . However, a full appreciation of the implications of these findings will only be possible when the precise role of both NO and PGE 2 in cartilage homeostasis and arthritis is clearly elucidated. In animal models of arthritis, inhibitors of either NOS or COX-2 can independently repress joint inflammation, concomitant with the attenuation of PGE 2 or NO synthesis [3, 4, 39] . In general, the effects of NO on cartilage are believed to decrease collagen synthesis [10] ; NO has also been implicated in promoting chondrocyte apoptosis [13] . PGE 2 is also believed to exert predominantly injurious effects known to exacerbate joint inflammation [40] , induce IL-1b expression [41] and promote metalloproteinase production [42] [43] [44] [45] . However, PGE 2 has also been reported to increase proteoglycan synthesis, suggesting a possible reparative role in cartilage [46] . It should be noted that NSAIDS (unlike the NOS inhibitor: L-NMA) inhibited both NO and PGE 2 production in each of the chondrocyte systems that we assessed. Furthermore, (unlike NSAIDS) L-NMA augmented PGE 2 production in OA-affected cartilage [22] and bovine chondrocytes stimulated in vitro. Such studies underscore the complexity of the regulation of NOS and COX-2 in tissues, and indicate that the pharmacological interference with one pathway may yield unanticipated effects upon the other. Taken together, these studies do indicate that drugs exhibiting selectivity towards both NOS and COX-2 may offer the potential for developing novel anti-inflammatory therapies with the potential to prevent progressive cartilage deterioration.
